FR11C0042I1 - - Google Patents
Info
- Publication number
- FR11C0042I1 FR11C0042I1 FR11C0042C FR11C0042I1 FR 11C0042 I1 FR11C0042 I1 FR 11C0042I1 FR 11C0042 C FR11C0042 C FR 11C0042C FR 11C0042 I1 FR11C0042 I1 FR 11C0042I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
- B65D81/3216—Rigid containers disposed one within the other
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Mechanical Engineering (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32416501P | 2001-09-21 | 2001-09-21 | |
PCT/US2002/029491 WO2003026652A1 (en) | 2001-09-21 | 2002-09-17 | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
FR11C0042I1 true FR11C0042I1 (en) | 2011-04-11 |
FR11C0042I2 FR11C0042I2 (en) | 2013-01-11 |
Family
ID=23262376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR11C0042C Active FR11C0042I2 (en) | 2001-09-21 | 2011-09-27 | COMPOUNDS CONTAINING LACTAME AND THEIR DERIVATIVES AS FACTOR XA INHIBITORS |
Country Status (40)
Country | Link |
---|---|
US (11) | US7338963B2 (en) |
EP (2) | EP2105436B1 (en) |
JP (2) | JP4249621B2 (en) |
KR (2) | KR100909141B1 (en) |
CN (5) | CN102617567A (en) |
AR (2) | AR037092A1 (en) |
AT (2) | ATE439360T1 (en) |
AU (2) | AU2002341693B2 (en) |
BE (1) | BE2011C034I2 (en) |
BR (1) | BRPI0212726B8 (en) |
CA (2) | CA2461202C (en) |
CH (1) | CH1427415H1 (en) |
CL (1) | CL2008002717A1 (en) |
CO (1) | CO5560567A2 (en) |
CY (2) | CY1110509T1 (en) |
DE (2) | DE60233335D1 (en) |
DK (1) | DK1427415T3 (en) |
ES (1) | ES2329881T3 (en) |
FR (1) | FR11C0042I2 (en) |
GE (1) | GEP20074098B (en) |
HK (1) | HK1061973A1 (en) |
HR (2) | HRP20040280B1 (en) |
HU (2) | HU228195B1 (en) |
IL (3) | IL160693A0 (en) |
IS (2) | IS3006B (en) |
LT (1) | LTPA2011012I1 (en) |
LU (1) | LU91888I2 (en) |
ME (2) | ME00090B (en) |
MX (1) | MXPA04002526A (en) |
MY (1) | MY137830A (en) |
NO (4) | NO328558B1 (en) |
NZ (1) | NZ531616A (en) |
PL (2) | PL204263B1 (en) |
PT (1) | PT1427415E (en) |
RS (2) | RS20080517A (en) |
RU (2) | RU2345993C2 (en) |
SI (1) | SI1427415T1 (en) |
UA (1) | UA78232C2 (en) |
WO (1) | WO2003026652A1 (en) |
ZA (1) | ZA200402184B (en) |
Families Citing this family (167)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI290136B (en) | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
US7365205B2 (en) | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
BR0211565A (en) * | 2001-08-09 | 2004-06-29 | Daiichi Seiyaku Co | Diamine derivatives |
SE0102764D0 (en) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
JP4249621B2 (en) | 2001-09-21 | 2009-04-02 | ブリストル−マイヤーズ スクイブ カンパニー | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
TWI320039B (en) * | 2001-09-21 | 2010-02-01 | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | |
TW200303201A (en) | 2001-12-10 | 2003-09-01 | Bristol Myers Squibb Co | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones |
AU2003297441A1 (en) * | 2002-12-24 | 2004-07-22 | Arena Pharmaceuticals, Inc. | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
KR20050110612A (en) * | 2002-12-25 | 2005-11-23 | 다이이찌 세이야꾸 가부시기가이샤 | Diamine derivatives |
JP4630267B2 (en) * | 2002-12-25 | 2011-02-09 | 第一三共株式会社 | Diamine derivatives |
US7205318B2 (en) * | 2003-03-18 | 2007-04-17 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors |
US7135469B2 (en) * | 2003-03-18 | 2006-11-14 | Bristol Myers Squibb, Co. | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors |
EP1608317B1 (en) | 2003-03-25 | 2012-09-26 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CA2533369C (en) * | 2003-07-22 | 2009-07-14 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN1867560A (en) | 2003-08-13 | 2006-11-22 | 武田药品工株式会社 | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
TW200512181A (en) * | 2003-09-26 | 2005-04-01 | Tanabe Seiyaku Co | Amide-type carboxamide derivatives |
US20050119266A1 (en) * | 2003-10-01 | 2005-06-02 | Yan Shi | Pyrrolidine and piperidine derivatives as factor Xa inhibitors |
EP1670739A4 (en) * | 2003-10-08 | 2007-08-08 | Bristol Myers Squibb Co | Cyclic diamines and derivatives as factor xa inhibitors |
KR101316999B1 (en) | 2004-02-24 | 2013-10-11 | 스미또모 가가꾸 가부시끼가이샤 | Insecticide composition |
US7371743B2 (en) | 2004-02-28 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Carboxylic acid amides, the preparation thereof and their use as medicaments |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005095381A1 (en) | 2004-03-15 | 2005-10-13 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CA2559038C (en) * | 2004-03-23 | 2013-09-10 | Arena Pharmaceuticals, Inc. | Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof |
US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
TWI396686B (en) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | Cyclic amide derivative, and its production and use |
ITMI20041032A1 (en) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | PHARMACEUTICAL COMPOSITES |
EP1753730A1 (en) | 2004-06-04 | 2007-02-21 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
CN101068812B (en) * | 2004-09-28 | 2010-09-29 | 布里斯托尔-迈尔斯斯奎布公司 | Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
US20060069085A1 (en) * | 2004-09-28 | 2006-03-30 | Rulin Zhao | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
US7304157B2 (en) | 2004-09-28 | 2007-12-04 | Bristol-Myers Squibb Company | Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
US7396932B2 (en) * | 2004-09-28 | 2008-07-08 | Bristol-Myers Squibb Company | Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
US7388096B2 (en) | 2004-09-28 | 2008-06-17 | Bristol-Myers Squibb Company | Crystalline forms of a factor Xa inhibitor |
US7381732B2 (en) * | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
PE20061130A1 (en) * | 2004-11-19 | 2007-01-05 | Arena Pharm Inc | 3-PHENYL-PIRAZOLE DERIVATIVES AS MODULATORS OF THE SEROTONIN 5-HT2A RECEPTOR |
DE102004059219A1 (en) * | 2004-12-09 | 2006-06-14 | Bayer Healthcare Ag | Pyrazine dicarboxylic acid amides and their use |
WO2006065853A2 (en) * | 2004-12-15 | 2006-06-22 | Bristol-Myers Squibb Company | Crystalline forms of a factor xa inhibitor |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
DE602006020327D1 (en) | 2005-01-19 | 2011-04-07 | Bristol Myers Squibb Co | 2-PHENOXY-N- (1,3,4-THIADIZOL-2-YL) PYRIDINE-3-AMINDER INHIBITOR FOR THE TREATMENT OF THROMBOEMBOLIC ILLNESSES |
US20060160841A1 (en) * | 2005-01-19 | 2006-07-20 | Chenkou Wei | Crystallization via high-shear transformation |
JP2006298909A (en) * | 2005-03-25 | 2006-11-02 | Tanabe Seiyaku Co Ltd | Medicine composition |
ATE505468T1 (en) | 2005-06-27 | 2011-04-15 | Bristol Myers Squibb Co | N-LINKED HETEROCYCLIC ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSIS |
US7714002B2 (en) | 2005-06-27 | 2010-05-11 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
US7700620B2 (en) | 2005-06-27 | 2010-04-20 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
ES2360818T3 (en) | 2005-06-27 | 2011-06-09 | Bristol-Myers Squibb Company | MIMETICS OF LINEAR UREA ANTAGONISTS OF THE P2Y RECEIVER, USEFUL IN THE TREATMENT OF THROMBOTHIC AFFECTIONS. |
US20070191306A1 (en) * | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
EP1942898B2 (en) | 2005-09-14 | 2014-05-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
CN102675221A (en) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | Intermediate in method for preparing pyrimidinedione derivative |
TW200734304A (en) * | 2005-11-08 | 2007-09-16 | Astellas Pharma Inc | Benzene derivative or salt thereof |
WO2007087246A2 (en) * | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Jak2 tyrosine kinase inhibition |
US20090227598A1 (en) * | 2006-01-24 | 2009-09-10 | Buser-Doepner Carolyn A | Ret Tyrosine Kinase Inhibition |
US8148418B2 (en) | 2006-05-18 | 2012-04-03 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
JP5406018B2 (en) | 2006-05-18 | 2014-02-05 | アリーナ ファーマシューティカルズ, インコーポレイテッド | Primary amines as modulators of 5-HT2A serotonin receptors useful for the treatment of disorders associated with 5-HT2A serotonin receptors, and derivatives thereof |
KR101514846B1 (en) | 2006-05-18 | 2015-04-23 | 아레나 파마슈티칼스, 인크. | - - crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor |
DE102006025314A1 (en) | 2006-05-31 | 2007-12-06 | Bayer Healthcare Ag | Aryl-substituted heterocycles and their use |
DE102006025315A1 (en) * | 2006-05-31 | 2007-12-06 | Bayer Healthcare Ag | Tetrahydro-pyrrolopyridine, tetrahydro-pyrazolopyridine, tetrahydro-imidazopyridine and tetrahydro-triazolopyridine derivatives and their use |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TWI415845B (en) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
DE102006051625A1 (en) | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Combination therapy of substituted oxazolidinones |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
WO2008076805A2 (en) | 2006-12-15 | 2008-06-26 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
PE20081775A1 (en) | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | MACROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
JP5309131B2 (en) | 2007-04-23 | 2013-10-09 | サノフイ | Quinoline-carboxamide derivatives as P2Y12 antagonists |
DE102007028407A1 (en) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituted oxazolidinones and their use |
DE102007028319A1 (en) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituted oxazolidinones and their use |
DE102007028406A1 (en) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituted oxazolidinones and their use |
DE102007032344A1 (en) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Prodrug derivatives of 1- (4-methoxyphenyl) -7-oxo-6- [4- (2-oxopiperidin-1-yl) phenyl] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4 -c] pyridine-3-carboxamide |
ES2421237T7 (en) | 2007-08-15 | 2013-09-30 | Arena Pharmaceuticals, Inc. | Imidazo [1,2-a] pyridine derivatives as modulators of the serotonergic 5ht2a receptor in the treatment of disorders related thereto |
JP5504171B2 (en) | 2007-12-26 | 2014-05-28 | サノフイ | Heterocyclic pyrazole-carboxamides as P2Y12 antagonists |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
WO2009134203A1 (en) * | 2008-04-30 | 2009-11-05 | Fredrik Almqvist | New peptidomimetic compounds |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
CN104739829B (en) | 2008-10-28 | 2018-11-06 | 艾尼纳制药公司 | For treating 5-HT2AThe 5-HT of 5-hydroxytryptamine receptor associated disorders2A5-hydroxytryptamine receptor regulating composition |
WO2011075596A1 (en) | 2009-12-18 | 2011-06-23 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
CN107973809B (en) | 2010-02-11 | 2023-06-30 | 百时美施贵宝公司 | Macrocyclic compounds as factor XIA inhibitors |
EP3017811B1 (en) | 2010-02-25 | 2018-12-05 | Bristol-Myers Squibb Holdings Ireland | Apixaban formulations |
CN103619883A (en) | 2011-01-19 | 2014-03-05 | 拜耳知识产权有限责任公司 | Binding proteins to inhibitors of coagulation factors |
US8884016B2 (en) | 2011-06-10 | 2014-11-11 | Dipharma Francis S.R.L. | Apixaban preparation process |
ITMI20111047A1 (en) * | 2011-06-10 | 2012-12-11 | Dipharma Francis Srl | CRYSTAL FORM OF APIXABAN |
EP2554159A1 (en) | 2011-08-04 | 2013-02-06 | ratiopharm GmbH | Dosage forms comprising apixaban and content uniformity enhancer |
TW201311689A (en) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | Novel macrocycles as factor XIa inhibitors |
TW201319068A (en) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | Cyclic P1 linkers as factor XIa inhibitors |
IN2014CN02805A (en) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
ES2572908T3 (en) | 2011-10-14 | 2016-06-03 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline compounds substituted as factor XIa inhibitors |
RS56168B1 (en) | 2011-10-14 | 2017-11-30 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
CN202271910U (en) * | 2011-10-31 | 2012-06-13 | 潘磊 | Multifunctional rearview mirror of automobile |
CN103242310A (en) * | 2012-02-10 | 2013-08-14 | 苏州迈泰生物技术有限公司 | Pyrazolo pyridone compound and its application in preparation of anticoagulant |
JP6082409B2 (en) | 2012-03-07 | 2017-02-15 | インスティチュート オブ キャンサー リサーチ:ロイヤル キャンサー ホスピタル | 3-Aryl-5-substituted isoquinolin-1-one compounds and therapeutic uses thereof |
WO2013146963A1 (en) * | 2012-03-28 | 2013-10-03 | 武田薬品工業株式会社 | Heterocyclic compound |
EP2854759B1 (en) | 2012-05-24 | 2019-12-18 | ratiopharm GmbH | Dosage forms comprising apixaban and matrix former |
AR091981A1 (en) | 2012-08-03 | 2015-03-11 | Bristol Myers Squibb Co | DIHYDROPIRIDONE P1 AS INHIBITORS OF THE XIA FACTOR |
UY34959A (en) | 2012-08-03 | 2014-01-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | DIHYDROPIRIDONE P1 AS INHIBITORS OF THE XIA FACTOR |
WO2014044107A1 (en) * | 2012-09-18 | 2014-03-27 | 上海恒瑞医药有限公司 | Pyrazol[3,4-c] pyridine derivative, preparation method and use in medicine thereof |
SG11201501743UA (en) * | 2012-09-26 | 2015-04-29 | Bristol Myers Squibb Co | Apixaban liquid formulations |
CN104797580A (en) * | 2012-10-10 | 2015-07-22 | 广东东阳光药业有限公司 | Crystalline form and amorphous form of apixaban and preparation thereof |
ES2664782T3 (en) * | 2012-11-05 | 2018-04-23 | Nantbio, Inc | Derivatives containing cyclic sulfonamide as inhibitors of the hedgehog signaling pathway |
CZ304846B6 (en) * | 2012-11-13 | 2014-12-03 | Zentiva, K.S. | Process for preparing APIXABAN |
EP2752414A1 (en) | 2013-01-04 | 2014-07-09 | Sandoz AG | Crystalline form of apixaban |
WO2014115020A1 (en) * | 2013-01-24 | 2014-07-31 | Universita' Degli Studi Di Bari | Heterocycles and their radiolabeled analogs useful as cox-1 selective inhibitors |
CN103539795A (en) * | 2013-03-18 | 2014-01-29 | 齐鲁制药有限公司 | Apixaban polymorph and preparation method thereof |
WO2014160668A1 (en) | 2013-03-25 | 2014-10-02 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
CN104109165A (en) * | 2013-04-19 | 2014-10-22 | 四川海思科制药有限公司 | 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-one derivatives, and preparation method and application thereof |
CZ2013305A3 (en) | 2013-04-23 | 2014-11-05 | Zentiva, K.S. | Novel crystalline forms of APIXABAN and process of their preparation |
WO2014203275A2 (en) | 2013-06-18 | 2014-12-24 | Cadila Healthcare Limited | An improved process for the preparation of apixaban and intermediates thereof |
CN104370902A (en) * | 2013-08-12 | 2015-02-25 | 药源药物化学(上海)有限公司 | Apixaban novel crystal form and preparation method thereof |
JP6456392B2 (en) | 2013-09-11 | 2019-01-23 | インスティチュート オブ キャンサー リサーチ:ロイヤル キャンサー ホスピタル | 3-Aryl-5-substituted isoquinolin-1-one compounds and therapeutic uses thereof |
CN104650072B (en) * | 2013-11-18 | 2016-03-16 | 成都苑东生物制药股份有限公司 | A kind of pyridine derivatives |
CR20160272A (en) | 2013-12-18 | 2016-08-16 | Glaxosmithkline Ip Dev Ltd | Nrf2 REGULATORS |
DK3099687T3 (en) | 2014-01-31 | 2018-10-22 | Bristol Myers Squibb Co | MACROCYCLES WITH HETEROCYCLIC P2 'GROUPS AS FACTOR XIA INHIBITORS |
NO2760821T3 (en) | 2014-01-31 | 2018-03-10 | ||
CN103923080B (en) * | 2014-04-04 | 2016-06-22 | 苏州景泓生物技术有限公司 | A kind of method preparing antithrombotic reagent Eliquis |
EP3147283B1 (en) * | 2014-05-22 | 2022-08-17 | North China Pharmaceutical Company., Ltd. | Hydrazine compound as blood coagulation factor xa inhibitor |
CN105085515B (en) * | 2014-05-22 | 2019-02-01 | 华北制药股份有限公司 | Hydrazide kind compound as coagulation factor xa inhibitors |
WO2015177801A1 (en) * | 2014-05-23 | 2015-11-26 | Symed Labs Limited | Novel process for the preparation of a lactam-containing compound |
DE102014108210A1 (en) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | rodenticide |
HU231122B1 (en) | 2014-08-06 | 2020-11-30 | Egis Gyógyszergyár Zrt | Process for the preparation of apixaban |
JP6667507B2 (en) * | 2014-09-02 | 2020-03-18 | 石薬集団中奇制薬技術(石家庄)有限公司 | Pyrazolo [3,4-c] pyridine derivatives |
CN104311557B (en) * | 2014-09-19 | 2016-01-06 | 广东东阳光药业有限公司 | Containing diketone substituent pyrazolo piperidone compounds and composition thereof and purposes |
CN104311555B (en) * | 2014-09-19 | 2016-04-20 | 广东东阳光药业有限公司 | Pyrazolo piperidone compounds and composition thereof and purposes |
CN104327074B (en) * | 2014-09-19 | 2016-01-06 | 广东东阳光药业有限公司 | Containing lactan substituent pyrazolo piperidone compounds and composition thereof and purposes |
CN104277040B (en) * | 2014-09-19 | 2016-04-20 | 广东东阳光药业有限公司 | Containing acyl piperazine ketone substituent pyrazolo piperidone compounds and composition thereof and purposes |
CN104311541B (en) * | 2014-09-19 | 2017-12-05 | 广东东阳光药业有限公司 | Containing substituted pyrazole compound of ketone and combinations thereof and purposes |
CN104277039B (en) * | 2014-09-19 | 2016-06-01 | 广东东阳光药业有限公司 | Contain the pyrazoles piperidone compounds and composition thereof and purposes that replace butynyl |
CN104277041B (en) * | 2014-09-19 | 2016-01-06 | 广东东阳光药业有限公司 | Aromatic nucleus containing substituent methyl substituent pyrazolo piperidone compounds and composition thereof and purposes |
NO2721243T3 (en) | 2014-10-01 | 2018-10-20 | ||
HU230991B1 (en) | 2014-11-19 | 2019-08-28 | Egis Gyógyszergyár Zrt. | Intermediate and process for the preparation of apixaban |
US9603846B2 (en) | 2014-11-25 | 2017-03-28 | Cadila Healthcare Limited | Process for the preparation of apixaban |
CN104530080B (en) * | 2014-12-10 | 2017-01-11 | 广东东阳光药业有限公司 | Oxazolidinone compounds and application thereof in drugs |
CN104513239B (en) * | 2014-12-10 | 2017-08-22 | 沈阳药科大学 | The ketone compounds of pyrazolo [3,4 c] pyridine 7 and its application |
EP3078378B1 (en) | 2015-04-08 | 2020-06-24 | Vaiomer | Use of factor xa inhibitors for regulating glycemia |
CN104892601B (en) * | 2015-06-09 | 2017-09-19 | 江苏中邦制药有限公司 | A kind of preparation method of antithrombotic reagent Eliquis |
RU2017145976A (en) | 2015-06-12 | 2019-07-15 | Аксовант Сайенсиз Гмбх | Diaryl- and arylheteroarylurea derivatives applicable for the prevention and treatment of behavioral disturbances during the REM phase of sleep |
JP6786527B2 (en) | 2015-06-15 | 2020-11-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2 regulator |
CN108112251B (en) | 2015-06-15 | 2021-03-05 | 葛兰素史克知识产权发展有限公司 | NRF2 modulators |
JP6742348B2 (en) | 2015-06-19 | 2020-08-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Diamide macrocycles as factor XIA inhibitors |
JP2018520187A (en) | 2015-07-15 | 2018-07-26 | アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH | Diaryl and arylheteroaryl urea derivatives as modulators of 5-HT2A serotonin receptors useful for the prevention and treatment of hallucinations associated with neurodegenerative diseases |
ES2871111T3 (en) | 2015-07-29 | 2021-10-28 | Bristol Myers Squibb Co | Macrocyclic factor XIa inhibitors containing a non-aromatic P2 'group |
JP6785838B2 (en) | 2015-08-05 | 2020-11-18 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | FXIA inhibitor of novel substitution glycine induction |
LT3355890T (en) * | 2015-10-01 | 2021-12-27 | Biocryst Pharmaceuticals, Inc. | Human plasma kallikrein inhibitors |
WO2017060854A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
EP3380083A1 (en) | 2015-11-26 | 2018-10-03 | Zentiva, K.S. | Preparation of a drug form containing amorphous apixaban |
US10752641B2 (en) | 2016-03-02 | 2020-08-25 | Bristol-Myers Squibb Company | Diamide macrocycles having factor XIa inhibiting activity |
WO2017221209A1 (en) | 2016-06-23 | 2017-12-28 | Lupin Limited | Pharmaceutical formulations of apixaban |
TW201815787A (en) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
TW201813963A (en) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
TW201825465A (en) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | Phosphatidylinositol 3-kinase inhibitors |
BR112019006712A2 (en) * | 2016-10-03 | 2019-06-25 | Sigilon Therapeutics Inc | compound, pharmaceutical composition, composition for use in treating a disease, implantable element, and device. |
CN107064367B (en) * | 2017-04-20 | 2019-09-13 | 青岛理工大学 | The analyzing detecting method of four kinds of heterocyclic pesticides in a kind of environmental water sample |
CN106940355B (en) * | 2017-04-24 | 2018-08-24 | 中国药科大学 | A kind of brufen, the detection method of its sodium salt and its preparation in relation to substance |
WO2019123194A1 (en) * | 2017-12-20 | 2019-06-27 | Pi Industries Ltd. | Anthranilamides, their use as insecticide and processes for preparing the same. |
EP3849979A1 (en) | 2018-09-12 | 2021-07-21 | Novartis AG | Antiviral pyridopyrazinedione compounds |
KR102188341B1 (en) | 2018-10-24 | 2020-12-08 | 하나제약 주식회사 | Method for Preparation of Apixaban |
AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
MX2021008661A (en) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof. |
EP3753924A1 (en) * | 2019-06-18 | 2020-12-23 | AnaMar AB | New tricyclic 5-ht2 antagonists |
US11667613B2 (en) | 2019-09-26 | 2023-06-06 | Novartis Ag | Antiviral pyrazolopyridinone compounds |
EP4069691A1 (en) | 2019-12-06 | 2022-10-12 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
JP7477642B2 (en) * | 2020-04-09 | 2024-05-01 | ディスアーム セラピューティクス, インコーポレイテッド | SARM1 inhibitors |
CA3221259A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
NL2029536B1 (en) | 2021-10-27 | 2023-05-26 | Pharma Data S A | Apixaban suspension and preparation method |
WO2023072967A1 (en) | 2021-10-27 | 2023-05-04 | Pharma-Data S.A. | Apixaban suspension and preparation method |
WO2024084217A1 (en) * | 2022-10-19 | 2024-04-25 | Kalvista Pharmaceuticals Limited | 3a,4,5,6-tetrahydro-1 h-pyrazolo[3,4-c]pyridin-7(7ah)-one derivatives as factor xiia inhibitors |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3365459A (en) | 1964-09-08 | 1968-01-23 | Ciba Geigy Corp | Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives |
US3340269A (en) | 1964-09-08 | 1967-09-05 | Ciba Geigy Corp | 1-substituted 4-acyl-2, 3-dioxo-piperidine |
US3423414A (en) | 1966-01-13 | 1969-01-21 | Ciba Geigy Corp | Pyrazolopyridines |
EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
WO1994020460A1 (en) | 1993-03-11 | 1994-09-15 | Smithkline Beecham Corporation | Chemical compounds |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
HUT77517A (en) | 1994-10-20 | 1998-05-28 | Pfizer Inc. | Bicyclic tetrahydro pyrazolopyridines and their use as medicaments |
US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
US5939418A (en) | 1995-12-21 | 1999-08-17 | The Dupont Merck Pharmaceutical Company | Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors |
US5925635A (en) | 1996-04-17 | 1999-07-20 | Dupont Pharmaceuticals Company | N-(amidinophenyl) cyclourea analogs as factor XA inhibitors |
US6057342A (en) | 1996-08-16 | 2000-05-02 | Dupont Pharmaceutical Co. | Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof |
US6548512B1 (en) | 1996-12-23 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
JP2001506271A (en) | 1996-12-23 | 2001-05-15 | デュポン ファーマシューティカルズ カンパニー | Heterocyclic aromatic compounds containing oxygen or sulfur as factor Xa inhibitors |
US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
US6020357A (en) | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
EP0946508B1 (en) | 1996-12-23 | 2009-09-23 | Bristol-Myers Squibb Pharma Company | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
US5998424A (en) | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
WO1998057937A2 (en) | 1997-06-19 | 1998-12-23 | The Du Pont Merck Pharmaceutical Company | Inhibitors of factor xa with a neutral p1 specificity group |
US6060491A (en) | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
CA2293824A1 (en) | 1997-06-19 | 1998-12-23 | Mimi Lifen Quan | (amidino)6-membered aromatics as factor xa inhibitors |
US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
ES2215337T3 (en) | 1997-12-19 | 2004-10-01 | Schering Aktiengesellschaft | ORTO-ANTRANILAMIDE DERIVATIVES AS ANTICOAGULANTS. |
US6271237B1 (en) * | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
EP1042299A1 (en) | 1997-12-22 | 2000-10-11 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
DE69920888T2 (en) | 1998-03-27 | 2006-02-02 | Bristol-Myers Squibb Pharma Co. | DISUBSTITUTED PYRAZOLINES AND TRIAZOLINES AS FACTOR XA INHIBITORS |
KR20010083092A (en) | 1998-07-06 | 2001-08-31 | 스티븐 비. 데이비스 | Biphenyl Sulfonamides as Dual Angiotensin Endothelin Receptor Antagonists |
US6249205B1 (en) * | 1998-11-20 | 2001-06-19 | Steward, Inc. | Surface mount inductor with flux gap and related fabrication methods |
US6858616B2 (en) | 1998-12-23 | 2005-02-22 | Bristol-Myers Squibb Pharma Company | Nitrogen containing heterobicycles as factor Xa inhibitors |
FR2787708B1 (en) * | 1998-12-23 | 2002-09-13 | Oreal | DYEING PROCESS USING AN ACTIVE METHYLENE COMPOUND AND A COMPOUND CHOSEN FROM AN ALDEHYDE, A KETONE, A QUINONE AND A DERIVATIVE OF DI-IMINO-ISOINDOLINE OR 3-AMINO-ISOINDOLONE |
BR9917080A (en) | 1998-12-23 | 2002-03-12 | Du Pont Pharm Co | Compound, pharmaceutical composition, use of the compound and method of treatment or prevention of thromboembolic dysfunction |
EP1140862A4 (en) * | 1998-12-23 | 2004-07-28 | Bristol Myers Squibb Pharma Co | THROMBIN OR FACTOR Xa INHIBITORS |
ATE241621T1 (en) | 1999-04-02 | 2003-06-15 | Bristol Myers Squibb Pharma Co | ARYLSULFONYLS AS FACTOR XA INHIBITORS |
DE19932813A1 (en) | 1999-07-14 | 2001-01-18 | Bayer Ag | Substituted phenyluracile |
KR20030011268A (en) | 1999-07-16 | 2003-02-07 | 브리스톨-마이어스 스퀴브 파마 컴퍼니 | Nitrogen Containing Heterobicycles As Factor Xa Inhibitors |
HUP0203954A2 (en) | 1999-09-17 | 2003-03-28 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor xa |
WO2001032628A1 (en) | 1999-11-03 | 2001-05-10 | Bristol-Myers Squibb Pharma Company | Cyano compounds as factor xa inhibitors |
US6407256B1 (en) * | 1999-11-03 | 2002-06-18 | Bristol Myers Squibb Co | Cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds as factor Xa inhibitors |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
EP1156569B1 (en) * | 2000-05-19 | 2003-07-09 | USM Holding AG | Wiring for modular furniture systems |
DE10112768A1 (en) * | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | New heterocyclic-substituted phenyl compounds, are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, restenosis or tumor diseases |
US6960595B2 (en) * | 2001-03-23 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors |
US6998408B2 (en) * | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
CA2441772A1 (en) * | 2001-04-18 | 2002-10-31 | Bristol-Myers Squibb Company | 1,4,5,6-tetrahydropyrazolo-¬3,4-c|-pyridin-7-ones as factor xa inhibitors |
EP1379245A4 (en) * | 2001-04-18 | 2006-07-26 | Bristol Myers Squibb Co | 1, 4, 5, 6-tetrahydropyrazolo- 3, 4-c|-pyrid in-7-ones as factor xa inhibitors |
WO2003009108A2 (en) | 2001-07-20 | 2003-01-30 | Compulaw, Llc | Method and apparatus for management of court schedules |
JP4249621B2 (en) | 2001-09-21 | 2009-04-02 | ブリストル−マイヤーズ スクイブ カンパニー | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
TWI320039B (en) | 2001-09-21 | 2010-02-01 | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | |
WO2003048081A2 (en) | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
TW200302225A (en) * | 2001-12-04 | 2003-08-01 | Bristol Myers Squibb Co | Substituted amino methyl factor Xa inhibitors |
TW200303201A (en) | 2001-12-10 | 2003-09-01 | Bristol Myers Squibb Co | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones |
EP1505966A4 (en) | 2002-05-10 | 2006-08-30 | Bristol Myers Squibb Co | 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors |
US7135469B2 (en) | 2003-03-18 | 2006-11-14 | Bristol Myers Squibb, Co. | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors |
US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
US6927187B2 (en) | 2003-07-11 | 2005-08-09 | Exxonmobil Chemical Patents Inc. | Synthesis of silicoaluminophosphates |
-
2002
- 2002-09-17 JP JP2003530289A patent/JP4249621B2/en not_active Expired - Lifetime
- 2002-09-17 CA CA2461202A patent/CA2461202C/en not_active Expired - Lifetime
- 2002-09-17 PT PT02775843T patent/PT1427415E/en unknown
- 2002-09-17 ME MEP-2008-87A patent/ME00090B/en unknown
- 2002-09-17 SI SI200230849T patent/SI1427415T1/en unknown
- 2002-09-17 UA UA20040402985A patent/UA78232C2/en unknown
- 2002-09-17 KR KR1020087018676A patent/KR100909141B1/en not_active IP Right Cessation
- 2002-09-17 CN CN2012100339134A patent/CN102617567A/en active Pending
- 2002-09-17 CA CA2726702A patent/CA2726702A1/en not_active Abandoned
- 2002-09-17 NZ NZ531616A patent/NZ531616A/en not_active IP Right Cessation
- 2002-09-17 AU AU2002341693A patent/AU2002341693B2/en active Active
- 2002-09-17 GE GE5556A patent/GEP20074098B/en unknown
- 2002-09-17 DE DE60233335T patent/DE60233335D1/en not_active Expired - Lifetime
- 2002-09-17 RU RU2004112191/04A patent/RU2345993C2/en active Protection Beyond IP Right Term
- 2002-09-17 RS RSP-2008/0517A patent/RS20080517A/en unknown
- 2002-09-17 CN CN201510072782.4A patent/CN104744461A/en active Pending
- 2002-09-17 WO PCT/US2002/029491 patent/WO2003026652A1/en active Search and Examination
- 2002-09-17 MX MXPA04002526A patent/MXPA04002526A/en active IP Right Grant
- 2002-09-17 IS IS8803A patent/IS3006B/en unknown
- 2002-09-17 BR BRPI0212726A patent/BRPI0212726B8/en active IP Right Grant
- 2002-09-17 AT AT02775843T patent/ATE439360T1/en active
- 2002-09-17 CN CN201910724975.1A patent/CN110894196A/en active Pending
- 2002-09-17 PL PL373299A patent/PL204263B1/en unknown
- 2002-09-17 IL IL16069302A patent/IL160693A0/en unknown
- 2002-09-17 ME MEP-2008-581A patent/ME00384B/en unknown
- 2002-09-17 EP EP09075313A patent/EP2105436B1/en not_active Expired - Lifetime
- 2002-09-17 HU HU0402463A patent/HU228195B1/en active Protection Beyond IP Right Term
- 2002-09-17 KR KR1020047004025A patent/KR100908176B1/en active IP Right Review Request
- 2002-09-17 ES ES02775843T patent/ES2329881T3/en not_active Expired - Lifetime
- 2002-09-17 PL PL386232A patent/PL204653B1/en not_active IP Right Cessation
- 2002-09-17 RS YUP-227/04A patent/RS51444B/en unknown
- 2002-09-17 CH CH02775843T patent/CH1427415H1/en unknown
- 2002-09-17 AT AT09075313T patent/ATE544750T1/en active
- 2002-09-17 EP EP02775843A patent/EP1427415B1/en not_active Expired - Lifetime
- 2002-09-17 CN CN028215370A patent/CN1578660B/en not_active Expired - Lifetime
- 2002-09-17 CN CNA200810210432XA patent/CN101357914A/en not_active Withdrawn
- 2002-09-17 DK DK02775843T patent/DK1427415T3/en active
- 2002-09-20 AR ARP020103556A patent/AR037092A1/en active IP Right Grant
- 2002-09-20 MY MYPI20023503A patent/MY137830A/en unknown
-
2004
- 2004-03-02 IL IL160693A patent/IL160693A/en active Protection Beyond IP Right Term
- 2004-03-16 IS IS7184A patent/IS2824B/en unknown
- 2004-03-18 ZA ZA2004/02184A patent/ZA200402184B/en unknown
- 2004-03-18 CO CO04025932A patent/CO5560567A2/en not_active Application Discontinuation
- 2004-03-19 HR HRP20040280AA patent/HRP20040280B1/en active IP Right Review Request
- 2004-03-19 NO NO20041163A patent/NO328558B1/en active Protection Beyond IP Right Term
- 2004-07-10 HK HK04105041.4A patent/HK1061973A1/en not_active IP Right Cessation
-
2005
- 2005-08-05 US US11/198,801 patent/US7338963B2/en not_active Expired - Lifetime
-
2007
- 2007-12-13 US US11/955,678 patent/US7531535B2/en not_active Expired - Lifetime
-
2008
- 2008-08-06 HR HR20080382A patent/HRP20080382A2/en not_active Application Discontinuation
- 2008-08-15 AR ARP080103585A patent/AR067965A2/en active IP Right Grant
- 2008-08-22 RU RU2008134413/04A patent/RU2008134413A/en not_active Application Discontinuation
- 2008-08-26 AU AU2008207537A patent/AU2008207537B8/en not_active Ceased
- 2008-08-27 NO NO20083684A patent/NO20083684L/en not_active Application Discontinuation
- 2008-09-12 CL CL2008002717A patent/CL2008002717A1/en unknown
- 2008-10-14 JP JP2008265280A patent/JP4889705B2/en not_active Expired - Lifetime
-
2009
- 2009-03-10 US US12/401,401 patent/US7691846B2/en not_active Expired - Lifetime
- 2009-10-21 CY CY20091101090T patent/CY1110509T1/en unknown
-
2010
- 2010-01-22 US US12/691,895 patent/US7960411B2/en not_active Expired - Fee Related
- 2010-01-26 IL IL203533A patent/IL203533A/en not_active IP Right Cessation
-
2011
- 2011-05-05 US US13/101,536 patent/US8188120B2/en not_active Expired - Lifetime
- 2011-09-26 NO NO2011021C patent/NO2011021I2/en unknown
- 2011-09-27 FR FR11C0042C patent/FR11C0042I2/en active Active
- 2011-09-28 DE DE201112100050 patent/DE122011100050I1/en active Pending
- 2011-09-28 CY CY2011016C patent/CY2011016I1/en unknown
- 2011-09-28 BE BE2011C034C patent/BE2011C034I2/fr unknown
- 2011-09-29 LT LTPA2011012C patent/LTPA2011012I1/en unknown
- 2011-10-19 LU LU91888C patent/LU91888I2/en unknown
-
2012
- 2012-04-12 US US13/444,999 patent/US8470854B2/en not_active Expired - Lifetime
-
2013
- 2013-04-24 HU HUS1300014C patent/HUS1300014I1/en unknown
- 2013-05-10 US US13/891,548 patent/US20140113892A1/en not_active Abandoned
-
2015
- 2015-04-08 US US14/681,743 patent/US20150210691A1/en not_active Abandoned
-
2016
- 2016-11-07 US US15/345,045 patent/US9975891B2/en not_active Expired - Lifetime
-
2018
- 2018-04-30 US US15/967,149 patent/US20180244673A1/en not_active Abandoned
-
2020
- 2020-01-08 US US16/737,261 patent/US20200140436A1/en not_active Abandoned
-
2023
- 2023-08-17 NO NO2023030C patent/NO2023030I1/en unknown